News
18mon MSN
The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...
On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.
The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover certain preventive services at no cost to patients in a 6-3 ruling. That’s ...
Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...
Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...
Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.
Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...
Friday is National HIV Testing Day, and it's an issue that's very important to metro Atlanta. Actor and advocate Miss ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results